CoChat

The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L

Open access
Hao, Bing-bing, Li, Xiao-jing, Jia, Xing-long, Wang, Yu-xing, Zhai, Lin-hui, Li, Duan-zhuo, Liu, Jie, Zhang, Die, Chen, Yu-lu, Xu, Yong-hu, Lee, Sang-kyu, Xu, Guo-feng, Chen, Xiao-hua, Dang, Yong-jun, Liu, Bin, Tan, Min-jia · 2020 · Acta Pharmacologica Sinica
Cited by 42

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Mitophagy is a degradative pathway that mediates the degradation of the entire mitochondria, and defects in this process are implicated in many diseases including cancer. In mammals, mitophagy is mediated by BNIP3L (also known as NIX) that is a dual regulator of mitochondrial turnover and programmed cell death pathways. Acute myeloid leukemia (AML) cells with deficiency of BNIP3L are more sensitive to mitochondria-targeting drugs. But small molecular inhibitors for BNIP3L are currently not available. Some immunomodulatory drugs (IMiDs) have been proved by FDA for hematologic malignancies, however, the underlining molecular mechanisms are still elusive, which hindered the applications of BNIP3L inhibition for AML treatment. In this study we carried out MS-based quantitative proteomics analysis to identify the potential neosubstrates of a novel thalidomide derivative CC-885 in A549 cells. In total, we quantified 5029 proteins with 36 downregulated in CRBN +/+ cell after CC-885 administration. Bioinformatic analysis showed that macromitophagy pathway was enriched in the negative pathway after CC-885 treatment. We further found that CC-885 caused both dose- and time-dependent degradation of BNIP3L in CRBN +/+ , but not CRBN −/− cell. Thus, our data uncover a novel role of CC-885 in the regulation of mitophagy by targeting BNIP3L for CRL4CRBN E3 ligase-dependent ubiquitination and degradation, suggesting that CC-885 could be used as a selective BNIP3L degradator for the further investigation. Furthermore, we demonstrated that CC-885 could enhance AML cell sensitivity to the mitochondria-targeting drug rotenone, suggesting that combining CC-885 and mitochondria-targeting drugs may be a therapeutic strategy for AML patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41401-020-0367-9

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 42

Metadata

Authors
Hao, B.-B., Li, X.-J., Jia, X.-L., Wang, Y.-X., Zhai, L.-H., Li, D.-Z., Liu, J., Zhang, D., Chen, Y.-L., Xu, Y.-H., Lee, S.-K., Xu, G.-F., Chen, X.-H., Dang, Y.-J., Liu, B., & Tan, M.-J.
Venue
Acta Pharmacologica Sinica
Published
2020-03-24
Volume
41
Issue
9
Pages
1246-1254
ISSN
  • 0253-9756 (ISSN-L)
  • 1671-4083
  • 1745-7254
OpenAlex
W3013416429
Cited by
42
References
16
FWCI
1.45
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L. https://app.cochat.ai/papers/10.1038/s41401-020-0367-9
The paper
Hao, B.-B., Li, X.-J., Jia, X.-L., Wang, Y.-X., Zhai, L.-H., Li, D.-Z., Liu, J., Zhang, D., Chen, Y.-L., Xu, Y.-H., Lee, S.-K., Xu, G.-F., Chen, X.-H., Dang, Y.-J., Liu, B., & Tan, M.-J. (2020). The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L. Acta Pharmacologica Sinica. https://doi.org/10.1038/s41401-020-0367-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.